A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.
Latest Information Update: 31 Jul 2019
At a glance
- Drugs Afatinib (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms UCGI 25
Most Recent Events
- 31 Jul 2019 Status changed from recruiting to completed.
- 02 Apr 2019 New trial record